Disruptive Pharma commercializes Formulite® through a flexible partnering model tailored to each partner’s objectives, development stage and project requirements.
The model includes formulation and product development projects, licensing agreements and strategic industrial collaborations. We work with pharmaceutical and biotechnology companies from early feasibility assessment and formulation development through product optimization, scale-up and lifecycle management (LCM).
In parallel, Disruptive Pharma is establishing strategic collaborations with contract development and manufacturing organizations, (CDMOs), to support broader industrial access to Formulite® and enable development and manufacturing at scale.
We welcome discussions with pharmaceutical, biotechnology and CDMO partners interested in applying Formulite® to challenging oral drug products.